Cardiovascular comorbidities associated with patients with chronic obstructive pulmonary disease – a hospital-based study

Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58:388–393.

Curkendall S, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16:63–70.

Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128:2640–2646.

Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from?A multiple cause coding analysis. Eur Respir J 2003; 22:809–814.

Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100:115–122.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2012. Available from: http://goldcopd.org

Gupta R. Burden of coronary heart disease in India. Indian Heart J 2005; 57:632–638.

Gupta R. Coronary heart disease in India: absolute numbers and economic burden. Rapid response to Ghaffar A, Reddy KS, Singhi M. Burden of non-communicable diseases in South Asia. Br Med J 2004; 328:807–810.

Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65:956–962.

Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009; 4:337–349.

Agusti A, Calverley PMA, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122.

Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32:962–969.

Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008; 63:599–605.

King DA, Cordova F, Scharf SM. Nutritional aspects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5:519–523.

Harik-Khan RI, Fleg JL, Wise RA. Body mass index and the risk of COPD. Chest 2002; 121:370–376.

Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006; 368:666–678.

Lusis AJ. Atherosclerosis. Nature 2000; 407:233–241

Verma S, LiSH, Badiwala MV, Weisel RD, Fedak PW, LiRK, et al. Endothelin antagonism and interleukin 6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105:1890–1896.

Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbation of COPD. Thorax 2011; 66:764–768.

McCullogh PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type Natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10:198–204.